What is claimed is:

1. A sulfonamide pharmaceutical composition, comprising the following raw materials:

Raw materials	Percentage by weight
Benzenesulfonamide compound	20%-40%
PEG-400	20%-40%
1,2-propanediol	5%-10%
Sebacic acid	2%-5%
2-ethyl-1,3-hexanediol	10%-20%
Dimethyl sulfoxide	0-10%
Anhydrous ethanol	0-10%

wherein the sulfonamide pharmaceutical composition is prepared by a process comprising the steps of:

1) adding the benzenesulfonamide compound, PEG-400, and 2-ethyl-1, 3-hexanediol into a container, stirring slowly at 85℃-95℃ to form a miscible solution, Solution A, for later use;

2) adding sebacic acid and 1,2-propanediol into a separate container, stirring slowly at 85℃-95℃ to form a miscible solution, Solution B, for later use;

3) mixing Solution A and Solution B while maintaining the temperature at 85℃-95℃, and stirring to obtain a homogenous solution for later use;


4) adding dimethyl sulfoxide and a small amount of anhydrous ethanol into a container, stirring and mixing well to obtain a homogenous solution, Solution C, for later use;


5) cooling the mixture of Solution A and Solution B to 60℃, adding Solution C to the mixture, stirring and mixing well before cooling down to room temperature, adding the remaining amount of anhydrous ethanol and mixing well;

6) filtering with 0.45 μm microporous membrane, aliquoting into 5 ml ampoules and sealing the ampoules; and


7) sterilizing at 121℃ for 30 minutes..

2. The sulfonamide pharmaceutical composition of claim 1, wherein the benzenesulfonamide compound is selected from one, or a mixture of two or more, at any ratio, of the following:



wherein R=H, C_2H_5, or .

3. The sulfonamide pharmaceutical composition of claim 1, wherein the benzenesulfonamide compound is:



.

4. The sulfonamide pharmaceutical composition of claim 1, wherein the benzensulfonamide compound is p-toluenesulfonamide.

5. The sulfonamide pharmaceutical composition of claim 1, wherein the sulfonamide pharmaceutical composition comprises the following raw materials:

Raw materials	Percentage by weight
p-Toluenesulfonamide	30%
PEG-400	30%
1,2-propanediol	8%
Sebacic acid	4%
2-ethyl-1,3-hexanediol	15%
Dimethyl sulfoxide	5%
Anhydrous ethanol	8%

.

6. The sulfonamide pharmaceutical composition of any one of claims 1-5, wherein said pharmaceutical composition is injectable.

7. A method to prepare said sulfonamide pharmaceutical composition of claim 1, comprising the steps of:

1) adding benzensulfonamide compound, PEG-400, and 2-ethyl-1, 3-hexanediol into a container, stirring slowly at 85℃ - 95℃ to form a miscible solution, Solution A, for later use;
2) adding sebacic acid and 1,2-propanediol, into a separate container, stirring slowly at 85℃ -95℃ to form a miscible solution, Solution B, for later use;
3) Mixing Solution A and Solution B while maintaining the temperature at 85℃ -95℃, and stirring to obtain a homogenous solution for later use;
4) adding dimethyl sulfoxide and a small amount of anhydrous ethanol into a container, stirring and mixing well to obtain a homogenous solution, Solution C, for later use;
5) Cooling the mixture of Solution A and Solution B to 60℃, adding Solution C to the mixture, stirring and mixing well before cooling down to room temperature, adding the remaining amount of anhydrous ethanol and mixing well;
6) Filtering with 0.45 um microporous membrane, aliquoting into 5 ml ampoules and sealing the ampoules; and
7) Sterilizing at 121℃for 30 minutes.

8. A method to prepare said sulfonamide pharmaceutical composition ofclaim 1, comprising the steps of:

Raw materials	Percentage by weight
p-Toluenesulfonamide	30%
PEG-400	30%
1,2-propanediol	8%

Sebacic acid	4%
2-ethyl-1,3-hexanediol	15%
Dimethyl sulfoxide	5%
Anhydrous ethanol	8%

1) adding p-toluenesulfonamide compound, PEG-400, and 2-ethyl-1, 3-hexanediol into a container, stirring slowly at 85℃ -95℃ to form a miscible solution, Solution A, for later use;
2) adding sebacic acid and 1,2-propanediol, into a separate container, stirring slowly at 85℃ -95℃ to form a miscible solution, Solution B, for later use;
3) Mixing Solution A and Solution B while maintaining the temperature at 85℃ -95℃, and stirring well to obtain a homogenous solution for later use;
4) adding dimethyl sulfoxide and a small amount of anhydrous ethanol into a container, stirring and mixing well to obtain a homogenous solution, Solution C, for later use;
5) Cooling the mixture of Solution A and Solution B to 60℃, adding Solution C to the mixture, stirring and mixing well before cooling down to room temperature, adding the remaining amount of anhydrous ethanol and mixing well;
6) Filtering with 0.45 um microporous membrane, aliquoting into 5 ml ampoules and sealing the ampoules; and
7) Sterilizing at 121℃ for 30 minutes.